Health Care [ 8/12 ] | Health Care Equipment & Supplies [ 46/75 ]
NASDAQ | Common Stock
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions.
In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation.
The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors.
The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017.
The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 10, 26 | 0.46 Decreased by -59.65% | 0.42 Increased by +9.52% |
| Nov 5, 25 | 0.38 Decreased by -45.71% | 0.35 Increased by +8.57% |
| Jul 30, 25 | 0.47 Increased by +38.24% | 0.41 Increased by +14.63% |
| Apr 28, 25 | 0.31 Decreased by -3.13% | 0.35 Decreased by -11.43% |
| Feb 4, 25 | 1.14 Increased by +60.56% | 0.47 Increased by +142.55% |
| Oct 30, 24 | 0.70 Increased by +14.75% | 0.61 Increased by +14.75% |
| Aug 1, 24 | 0.34 Decreased by -52.78% | 0.38 Decreased by -10.53% |
| May 2, 24 | 0.32 Decreased by -38.46% | 0.41 Decreased by -21.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 103.85 M Increased by +6.13% | 27.02 M Decreased by -67.35% | Increased by +26.02% Decreased by -69.24% |
| Sep 30, 25 | 93.17 M Decreased by -28.46% | 21.86 M Decreased by -57.12% | Increased by +23.47% Decreased by -40.06% |
| Jun 30, 25 | 95.60 M Increased by +10.59% | 26.74 M Increased by +12.28% | Increased by +27.97% Increased by +1.53% |
| Mar 31, 25 | 77.87 M Decreased by -3.00% | 18.20 M Decreased by -23.19% | Increased by +23.37% Decreased by -20.81% |
| Dec 31, 24 | 97.85 M Decreased by -22.82% | 82.77 M Increased by +50.04% | Increased by +84.59% Increased by +94.40% |
| Sep 30, 24 | 130.23 M Increased by +5.78% | 50.99 M Increased by +9.61% | Increased by +39.15% Increased by +3.62% |
| Jun 30, 24 | 86.45 M Decreased by -36.47% | 23.82 M Decreased by -57.26% | Increased by +27.55% Decreased by -32.72% |
| Mar 31, 24 | 80.28 M Decreased by -24.31% | 23.70 M Decreased by -41.50% | Increased by +29.52% Decreased by -22.71% |